Company intelligence / Profile preview

AllVascular

Sydney, New South Wales, Australiaallvascular.com ↗

Ownership: Private
Development stage: Other

Overview

AllVascular developed the AVAS®, an innovative vascular access device enabling isolated and targeted intraarterial delivery of anti-cancer agents to solid tumors. Clinical evidence includes SYS-CAPLIOX study data for colorectal liver metastases, with pilot studies also underway or planned for pancreatic cancer. The device has regulatory approvals in the UK, EU, and Australia; US FDA Breakthrough Designation submission was completed with outcome pending as of April 2022.

Therapeutic areas: Oncology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on AllVascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllVascular.

Explore the full profile